InnoBiopharm was founded in 2016 with aspiration of improving research and development of important new medicine. There are many diseases with patients of unmet medical need still wanting novel medicine for their treatment, including cancer, immune related diseases, and patients with aging related diseases.
WHAT CAN WE DO?
AB VIVA is InnoBiopharm’s platform for novel selection of antibody hits, antibody leads and antibody candidates. Compared to polyclonal antibodies, our AB VIVA antibodies are human derived, have desirable clinical candidate characteristics, carry better manufacturing criteria, and can be designed to have important clinical features. AB VIVA is geared for your future drug development success.